This study is in progress, not accepting new patients
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Summary
- Eligibility
- for females ages 18-130 (full criteria)
- Location
- at San Francisco 5391959, California 5332921 and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Edwin Alvarez
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Edwin Alvarez
Professor, Ob/Gyn, Reproductive Sciences, School of Medicine. Authored (or co-authored) 6 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT03737643
- Phase
- Phase 3 Ovarian Cancer Research Study
- Study Type
- Interventional
- Participants
- About 1407 people participating
- Last Updated